| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Consumer health outlet |
| Population | Men |
| Source | Ubie Health (Doctor's Note) |
| URL | ubiehealth.com/doctors-note/testosterone-prostate-cancer-risk-trt-modern-dx-7733e1 (opens in a new tab) |
Specific Claim Evaluated
There is no convincing evidence that testosterone therapy causes prostate cancer in men who are properly screened and monitored, although PSA can rise modestly and rapid rises require evaluation.
Primary Research Supporting or Contradicting the Claim
In TRAVERSE, among men screened to exclude high prostate cancer risk, the incidence of high-grade or any prostate cancer did not differ between testosterone and placebo, and PSA rose more with testosterone in the initial year (Bhasin and Thompson, 2024).
Corrected Evidence-Based Interpretation
The article is correct.
Rationale for Grade
The page qualifies its statement by screening and monitoring, describes expected PSA changes and limits therapy after prostate cancer to specialist care.
References
- Bhasin S, Thompson IM. Prostate risk and monitoring during testosterone replacement therapy. J Clin Endocrinol Metab. 2024;109(8):1975-1983. PMID
Supporting excerpt: "were low and did not differ between the testosterone and placebo groups"